Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it.
Sirius NeoSight has raised $4.6M in total funding. The most recent round was Seed. The last funding was announced in February 2025.
Sirius NeoSight's investors include GO CAPITAL, Demeter, Better Angle, Evolem Start, Angels Santé.
Sirius NeoSight is headquartered in Lyon, France.
Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it.
Sirius NeoSight is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sirius NeoSight — Funding & Investors." VCBacked, February 4, 2025, https://www.vcbacked.co/company/sirius-neosight. Accessed August 14, 2026.
VCBacked. (2025). Sirius NeoSight — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/sirius-neosight
{{cite web |title=Sirius NeoSight — Funding & Investors |url=https://www.vcbacked.co/company/sirius-neosight |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated